Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.
Shin Nippon Biomedical Laboratories Dividend Announcement
• Shin Nippon Biomedical Laboratories announced a semi annually dividend of ¥30.00 per ordinary share which will be made payable on 2025-06-01. Ex dividend date: 2025-03-28
• Shin Nippon Biomedical Laboratories's trailing twelve-month (TTM) dividend yield is 3.16%
Shin Nippon Biomedical Laboratories Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2025-03-28 | ¥30.00 | semi annually | 2025-06-01 |
2024-09-27 | ¥20.00 | semi annually | 2024-11-29 |
2024-03-28 | ¥30.00 | semi annually | |
2023-09-28 | ¥20.00 | semi annually | 2023-11-30 |
2023-03-30 | ¥30.00 | semi annually | 2023-06-28 |
2022-09-29 | ¥20.00 | semi annually | 2022-11-30 |
2022-03-30 | ¥10.00 | semi annually | 2022-06-29 |
2021-03-30 | ¥10.00 | semi annually | 2021-06-30 |
2020-03-30 | ¥5.00 | semi annually | 2020-03-30 |
2019-03-27 | ¥3.00 | semi annually | 2019-06-29 |
2011-03-29 | ¥3.00 | semi annually | |
2010-03-29 | ¥3.00 | semi annually | |
2009-03-26 | ¥3.00 | semi annually | |
2008-03-26 | ¥3.00 | semi annually | |
2007-03-27 | ¥3.00 | semi annually |
Shin Nippon Biomedical Laboratories Dividend per year
Shin Nippon Biomedical Laboratories Dividend growth
Shin Nippon Biomedical Laboratories Dividend Yield
Shin Nippon Biomedical Laboratories current trailing twelve-month (TTM) dividend yield is 3.16%. Interested in purchasing Shin Nippon Biomedical Laboratories stock? Use our calculator to estimate your expected dividend yield:
Shin Nippon Biomedical Laboratories Financial Ratios
Shin Nippon Biomedical Laboratories Dividend FAQ
Other factors to consider when evaluating Shin Nippon Biomedical Laboratories as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Shin Nippon Biomedical Laboratories stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Shin Nippon Biomedical Laboratories's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Shin Nippon Biomedical Laboratories publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Shin Nippon Biomedical Laboratories distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Shin Nippon Biomedical Laboratories are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Shin Nippon Biomedical Laboratories sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Shin Nippon Biomedical Laboratories distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Shin Nippon Biomedical Laboratories declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Shin Nippon Biomedical Laboratories's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Shin Nippon Biomedical Laboratories's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.